Tata Chemicals Ltd (TATACHEM)

Chemicals · Chemicals · NSE · Updated 2 September 2026
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
₹633.55 ↓ 31.99% (1Y)

🎯 Key Takeaways

  • Tata Chemicals is undergoing a strategic transformation from a cyclical commodity chemicals producer to a higher-margin, sustainability-driven enterprise focused on non-cyclical segments like Living and Farm Essentials. Despite near-term margin pressure from export pricing challenges, the company is actively reshaping its portfolio, reducing net debt, and investing in future growth areas such as silica and sodium-ion batteries, positioning itself for long-term structural improvement.
  • Revenue grew 23.8% QoQ to ₹4,255 in Q1FY27.
  • ⚠️ Persistent margin pressure in export-oriented soda ash and commodity segments due to global oversupply and geopolitical cost headwinds, particularly i
Market Cap
₹16,140
P/B Ratio
0.76
ROE
-9.3%
ROCE
-4.0%
Debt/Equity
0.34
Div Yield
1.74%
Promoter
38.0%

📖 The Story

Tata Chemicals is undergoing a strategic transformation from a cyclical commodity chemicals producer to a higher-margin, sustainability-driven enterprise focused on non-cyclical segments like Living and Farm Essentials. Despite near-term margin pressure from export pricing challenges, the company is actively reshaping its portfolio, reducing net debt, and investing in future growth areas such as silica and sodium-ion batteries, positioning itself for long-term structural improvement.

📰 What's Happening

In Q1FY27, Tata Chemicals reported consolidated revenue growth of 14% YoY to ₹4,255 crores, driven by strong performance in Living and Farm Essentials segments, while standalone EBITDA rose 35% and PAT improved sharply from a ₹279 crore loss in Q4FY26 to ₹60 crores. The company reclassified its operations into Living, Industry, and Farm Essentials to emphasize non-cyclical, sustainability-linked revenue streams, with Living Essentials now driving capex allocation and long-term growth. Management highlighted the UKEBITDA breakeven target for full year 2026 and ongoing sodium-ion battery pilot testing, concluding by end-2026. Capex for FY27 is aligned with depreciation at ₹1,200 crores, reflecting disciplined investment in strategic expansion, including silica projects and non-core asset monetization planned for H2 FY27.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

MetricSep 2025Dec 2025Mar 2026Jun 2026
Revenue3,8773,5503,4384,255
Operating Profit25252-69219
OPM %6.5%1.5%-2.0%5.2%
Net Profit154-69-2,11660
EPS₹3.02₹-3.65₹-83.68₹-0.67

The company's financial trajectory shows a clear inflection point: after years of losses, Tata Chemicals has returned to profitability with ₹60 crores net profit in Q1FY27, reversing a ₹279 crore loss in the prior quarter, while revenue growth remains robust at 14% YoY. However, standalone EBITDA declined 15% YoY to ₹555 crores due to export pricing pressures, and OPM fell to 13.16% from 15.45% in Q2FY25, indicating ongoing margin compression in commodity segments. The sharp PAT recovery is attributed to volume growth and improved realizations despite lower overseas pricing, supported by asset monetization that reduced net debt by INR 5,692 crores QoQ. This suggests that while operational profitability is stabilizing, structural margin improvement will depend on the success of the Living Essentials shift and de-commoditization efforts.

🔮 Management Outlook & What's Next

Management has explicitly outlined a strategic pivot toward sustainable, non-cyclical growth, emphasizing that Living Essentials now drive both revenue expansion and capital allocation decisions. Key forward-looking statements include the expectation of UKEBITDA breakeven by full year 2026, completion of sodium-ion battery pilot testing by end-2026, and continued focus on capacity expansion in soda ash and bicarbonate to support long-term demand from solar PV and EV sectors. The company also plans to monetize non-core assets in H2 FY27, signaling a disciplined approach to portfolio optimization and value creation from its sustainability-linked businesses.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

ItemMar 2025Mar 2025Mar 2026Mar 2026
Equity Capital255255255255
Reserves21,94021,33922,10320,951
Borrowings6,4797,0727,4957,114
Total Liabilities37,62137,78038,85539,031
Fixed Assets8,0098,8449,02420,596
Investments9,9169,1449,5559,916
Total Assets37,62137,78038,85539,031

The balance sheet reflects a deliberate and aggressive deleveraging strategy, with net debt declining by INR 5,692 crores QoQ to ₹5,692 crores as of June 2026, driven by asset monetization and improved cash flow generation. This reduction enhances financial flexibility and supports the company’s strategic investments in Living Essentials and future growth areas without over-leveraging. While total assets remain stable around ₹38,855 crores, the improving equity base and controlled borrowing levels suggest a shift toward a more resilient capital structure, aligning with management’s focus on sustainable growth and prudent capital allocation.

💰 Cash Flow Statement (₹ Cr)

ItemMar 2026
Operating+1,269
Investing-809
Financing-670
Net Cash Flow-210

👥 Shareholding Pattern

CategoryQ2FY26Q3FY26Q4FY26Q1FY27
Promoters38.0%38.0%38.0%38.0%
FII13.7%12.3%11.9%12.1%
DII22.2%22.4%22.8%21.1%
Public22.2%23.4%23.4%24.1%
# Shareholders6,50,6936,50,5856,43,0786,37,200

Shareholding patterns indicate growing confidence among institutional investors, with FII ownership increasing from 11.9% in Q4FY26 to 12.07% in Q1FY27 and DII rising from 22.84% to 21.12% over the same period, despite a slight decline in public holding. Promoter holding remains stable at 37.98%, suggesting no erosion in stakeholder confidence. The rising institutional interest aligns with the company’s strategic refocus on sustainable growth and improved profitability, potentially signaling renewed investor interest in its transformation narrative, even as retail participation remains steady.

⚖️ Peer Comparison — Chemicals

Company MCap (₹ Cr) P/E ROCE ROE D/E
PIDILITIND 1.67 L Cr 63.2 33.4% 24.7% 0.01
SRF 76,535 35.4 15.6% 15.4% 0.36
LINDEINDIA 54,418 99.6 17.5% 12.8% 0.00
FLUOROCHEM 52,063 85.1 9.6% 7.7% 0.34
NAVINFLUOR 44,292 56.0 22.2% 19.9% 0.31
GODREJIND 38,842 33.0 9.2% 19.8% 4.57
HSCL 34,339 42.7 20.7% 17.1% 0.16
DEEPAKNTR 24,328 31.1 15.3% 13.4% 0.26
AETHER 22,349 94.8 13.8% 10.6% 0.08
AARTIIND 19,030 35.8 9.2% 9.5% 0.68

⚠️ Risk Factors

1. Persistent margin pressure in export-oriented soda ash and commodity segments due to global oversupply and geopolitical cost headwinds, particularly in Southeast Asia. 2. Execution risk in the Living Essentials transformation, including the scalability of new silica capacity and successful monetization of non-core assets in H2 FY27. 3. Commodity price volatility and foreign exchange fluctuations impacting overseas realizations, which have already contributed to EBITDA and PAT declines despite volume growth. 4. High goodwill impairment exposure, as evidenced by a ₹1,837 crore impairment in Q3 FY2026, which could reoccur if strategic investments underperform or market conditions deteriorate.

📋 Recent Filings

🧠 Analyst's Read

Tata Chemicals is at an inflection point, transitioning from a loss-making commodity player to a strategically focused, sustainability-led enterprise with improving profitability and disciplined capital allocation. Investors should monitor the pace of Living Essentials growth, margin recovery in non-cyclical segments, and successful execution of asset monetization in H2 FY27 as key catalysts for future performance.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when TATACHEM files new disclosures

Track TATACHEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TATACHEM — Free

Free account · 2 AI queries/day